Spots Global Cancer Trial Database for A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
Official Title: A Phase 1, Multicenter, Open-label Study to Evaluate the Safety and Preliminary Efficacy of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma and Determine the Recommended Dose for Each Add-on Investigational Component
Study ID: NCT06121843
Conditions
Study Description
Brief Summary: The purpose of this study is to establish a safe and tolerable dose of BMS-986393 in combinations with alnuctamab, mezigdomide, and iberdomide in participants with relapsed and/or refractory multiple myeloma (RRMM).
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of Alabama at Birmingham, Birmingham, Alabama, United States
Local Institution - 0002, Phoenix, Arizona, United States
City of Hope Comprehensive Cancer Center, Duarte, California, United States
Local Institution - 0005, Jacksonville, Florida, United States
Northside Hospital, Atlanta, Georgia, United States
Local Institution - 0011, Boston, Massachusetts, United States
Local Institution - 0027, Boston, Massachusetts, United States
Local Institution - 0001, Rochester, Minnesota, United States
Local Institution - 0010, Omaha, Nebraska, United States
Local Institution - 0004, Hackensack, New Jersey, United States
Local Institution - 0007, Buffalo, New York, United States
Laura and Isaac Perlmutter Cancer Center, New York, New York, United States
Columbia University Irving Medical Center, New York, New York, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Local Institution - 0023, Pittsburgh, Pennsylvania, United States
Local Institution - 0025, Nashville, Tennessee, United States
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Local Institution - 0013, Calgary, Alberta, Canada
Local Institution - 0024, Toronto, Ontario, Canada
Contact Details
Name: Bristol-Myers Squibb
Affiliation: Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
